TheEdgeResearch
Home / Stocks / MGRX

Mangoceuticals, Inc. (MGRX)

NASDAQ Healthcare Medical - Healthcare Information Services
$0.47 ▲ +0.41%
Market Cap
$7.9M
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Beta
2.05
52-Wk Range
0.162-2.75
CEO
Jacob D. Cohen
Country
US
Currency
USD

Mangoceuticals, Inc. operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Dallas, TX, US. The stock last traded at $0.47, up 0.41% on the session, giving a market capitalisation of $7.9M. On trailing twelve-month figures it carries a trailing P/E of -0.40, a net margin of -4791.5%. Its beta of 2.05 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.40
Price / Sales
25.08
Price / Book
0.64
EV / EBITDA
-0.58
Gross margin
54.4%
Operating margin
-4185.1%
Net margin
-4791.5%
Return on equity
—
Debt / equity
0.03
Current ratio
0.18
Dividend yield
0.0%
Payout ratio
-3.9%
Company profile
Exchange
NASDAQ Capital Market
Employees
3
IPO date
2023-03-21
Headquarters
Dallas, TX, US
About Mangoceuticals, Inc.

Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.

Comparable companies

Mangoceuticals, Inc. is most often compared with the following Healthcare names:

ASBPCASICINGCLSDENTOFEMYHCTIPALITOIVSEE
More research on MGRX
MGRX technical analysis MGRX TheEdge Score Compare against peers
Open full interactive analysis & DCF →